In this periodic feature, PharmAsia News highlights recent analyst notes with a unique viewpoint on Asia or other emerging markets
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
